The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants
Cao, L.; Li, Y.; Yang, S.; Li, G.; Zhou, Q.; Sun, J.; Xu, T.; Yang, Y.; Zhu, T.; Huang, S.; Ji, Y.; Cong, F.; Luo, Y.; Zhu, Y.; Luan, H.; Zhang, H.; Chen, J.; Liu, X.; Wang, P.; Yu, Y.; Xing, F.; Ke, B.; Zheng, H.; Deng, X.; Zhang, W.; Li, C.; Zhang, Y.; Zhao, J.; Zhang, X.; Guo, D.
Show abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the COVID-19 pandemic, is rapidly evolving. Due to the limited efficacy of vaccination in prevention of SARS-CoV-2 transmission and continuous emergence of variants of concern (VOC), including the currently most prevalent Delta variant, orally bioavailable and broadly efficacious antiviral drugs are urgently needed. Previously we showed that adenosine analogue 69-0 (also known as GS-441524), possesses potent anti-SARS-CoV-2 activity. Herein, we report that esterification of the 5-hydroxyl moieties of 69-0 markedly improved the antiviral potency. The 5-hydroxyl-isobutyryl prodrug, ATV006, showed excellent oral bioavailability in rats and cynomolgus monkeys and potent antiviral efficacy against different VOCs of SARS-CoV-2 in cell culture and three mouse models. Oral administration of ATV006 significantly reduced viral loads, alleviated lung damage and rescued mice from death in the K18-hACE2 mouse model challenged with the Delta variant. Moreover, ATV006 showed broad antiviral efficacy against different mammal-infecting coronaviruses. These indicate that ATV006 represents a promising oral drug candidate against SARS-CoV-2 VOCs and other coronaviruses.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice 96%
- Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 95%
- Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo 95%
Similar papers in this journal
- A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus 95%
- Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms 93%
- Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2 93%
Similar papers in this journal
- ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus Blocker 94%
- Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development 94%
- An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants 93%
Similar papers in this journal
Similar papers in this journal
- Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2 97%
- Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques 92%
- Structural and molecular basis for foot-and-mouth disease virus neutralization by two potent protective antibodies 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.